Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina

Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina

Abstract Background Sacubitril/valsartan (an Angiotensin receptor-neprilysin inhibitor—ARNI) is one of the cornerstones in the management of patients with heart failure with reduced ejection fraction (HFrEF) having demonstrated significant reductions in both mortality and hospitalisations as compare...

Full description

Bibliographic Details
Main Authors: Mariano A. Giorgi, Carlos P. Boissonnet, Paula Soledad Luque, Jimena Piastrella, Carlos Porley, Fernanda Ditata, Sergio Volman
Format: Article
Language:English
Published: BMC 2023-02-01
Series:Health Economics Review
Subjects:
Cost-effectiveness
Heart failure
Discount rate
Online Access:https://doi.org/10.1186/s13561-023-00427-w

Similar Items

Similar Items